OTTAWA, ONTARIO--(Marketwired - Feb. 25, 2016) - Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Galderma Canada Inc. failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations. The proceeding relates to the medicines branded as Differin, Differin XP, TactuPump, and TactuPump Forte. These medicines are generally indicated for the treatment of acne.
The purpose of the hearing is to receive evidence and argument of Board Staff, Galderma Canada Inc., and any interveners regarding allegations that Galderma Canada Inc. is in breach of its reporting requirements. The date, time, and location of the public hearing will be set and confirmed at a later date.
Those wishing to participate in this proceeding must apply to the Board for leave to intervene by April 4, 2016. For further information on the application process, please contact:
Guillaume Couillard |
Director, Board Secretariat |
Patented Medicine Prices Review Board |
Box L40, 333 Laurier Avenue West, Suite 1400 |
Ottawa, Ontario K1P 1C1 |
Telephone: 613-954-8299 |
Fax: 613-952-7626 |
E-mail: Guillaume.Couillard@pmprb-cepmb.gc.ca |
Quick Facts
Related Products
- Notice of Application - Failure to File
Associated Links
- Patent Act (Justice Canada)
- Patented Medicines Regulations (Justice Canada)
- Status of Ongoing Proceedings (Patented Medicine Prices Review Board)
Contact Information: